EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study

Rentong Gu, Tao Liu, Wen Cheng, Mengxing Li, Xiaowei Wang, Hai Jin iD

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70446 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Rentong Gu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Esophageal Squamous Cell Carcinoma, Tumor Burden, Esophageal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oesophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with limited biomarkers for monitoring tumour burden and prognosis. Circulating tumour DNA (ctDNA) has emerged as a promising tool for real‐time disease assessment, but its clinical utility in ESCC remains underexplored.

Methods

In this prospective cohort study, we analysed preoperative and postoperative ctDNA from 54 treatment‐naïve ESCC patients undergoing radical surgery using a 61‐gene panel. Associations between ctDNA mutations, clinicopathological characteristics and survival outcomes were evaluated.

Results

Preoperative ctDNA mutations were detected in 96.3% of patients (52/54), with Tumour Protein 53 (TP53) (59.3%), Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA) (31.5%) and Phosphatase and Tensin Homologue (PTEN) (13.0%) being most prevalent. Surgical resection significantly reduced ctDNA positivity ( p < .0001). Advanced‐stage tumours exhibited higher frequencies of PIK3CA (47.8% vs. 19.4%, p = .026) and PTEN mutations (26.1% vs. 3.2%, p = .034). Survival analysis revealed that postoperative TP53 ctDNA positivity predicted worse disease‐free survival (DFS; Hazard Ratio (HR) = 3.64, p = .005) and overall survival (OS; HR = 3.29, p = .009), while PIK3CA positivity was associated with improved OS ( p = .032). Strikingly, preoperative PTEN ctDNA‐positive patients showed dramatically worse outcomes, with median DFS of 4.01 versus 33.27 months (HR = 7.53, p < .001) and OS of 11.80 versus 45.17 months (HR = 5.35, p < .001). In multivariate analysis, preoperative PTEN positivity remained the strongest independent prognostic factor for both DFS (HR = 7.28, p = .002) and OS (HR = 3.76, p = .028), surpassing Tumour, Node, Metastasis (TNM) stage.

Conclusions

Our findings highlight the dynamic role of ctDNA in reflecting ESCC tumour burden and prognosis. While tumour‐agnostic ctDNA analysis showed limited clinical utility, gene‐specific mutations (TP53, PIK3CA and PTEN) demonstrated significant prognostic value. Preoperative PTEN ctDNA positivity emerged as a robust predictor of aggressive disease, suggesting its potential for risk stratification and personalised therapeutic strategies in ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAEsophageal Squamous Cell CarcinomaTumor BurdenEsophageal NeoplasmsHumansMaleFemaleMiddle AgedProspective StudiesAgedPrognosisBiomarkers, TumorMutationAdultPTEN PhosphohydrolaseClass I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

PIK3CAPTENTP53circulating tumour DNA (ctDNA)oesophageal squamous cell carcinoma (ESCC)prognosis

Substanzen

Circulating Tumor DNABiomarkers, TumorPTEN PhosphohydrolaseClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Changhai Hospital, Naval Medical University, Shanghai, China.
  • Department of Thoracic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • Department of Thoracic Surgery, Peking University First Hospital, Beijing, China.
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.

ORCID-Profile: Hai Jin

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Gu, R., Liu, T., Cheng, W., Li, M., Wang, X., & Jin, H. (2025). Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70446

Vancouver

Gu R, Liu T, Cheng W, Li M, Wang X, Jin H. Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70446

BibTeX
@article{Gu2025,
  author = {Gu, Rentong and Liu, Tao and Cheng, Wen and Li, Mengxing and Wang, Xiaowei and Jin, Hai},
  title = {Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70446}
}
Kostenlos starten →